Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver

Tomoko Sugiura, Sayaka Kato, Takuya Shimizu, Tomohiko Wakayama, Noritaka Nakamichi, Yoshiyuki Kubo, Daisuke Iwata, Kazuhiro Suzuki, Tomoyoshi Soga, Masahide Asano, Shoichi Iseki, Ikumi Tamai, Akira Tsuji, Yukio Kato

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Carnitine/organic cation transporter (OCTN1/SLC22A4) accepts various therapeutic agents as substrates in vitro and is expressed ubiquitously, although its function in most organs has not yet been examined. The purpose of the present study was to evaluate functional expression of OCTN1 in small intestine and liver, using octn1 gene knockout [octn1(-/-)] mice. After oral administration of [3H]ergothioneine ([3H]ERGO), a typical substrate of OCTN1, the amount of [3H]ERGO remaining in the small intestinal lumen was much higher in octn1(-/-) mice than in wild-type mice. In addition, uptake of [3H]ERGO by human embryonic kidney 293 cells heterologously expressing OCTN1 gene product and uptake of [3H]ERGO at the apical surface of intestinal everted sacs from wild-type mice were inhibited by OCTN1 substrates, tetraethylammonium and verapamil. Immunohistochemical analysis revealed that OCTN1 is localized on the apical surface of small intestine in mice and humans. These results suggest that OCTN1 is responsible for small intestinal absorption of [3H]ERGO. However, the plasma concentration of [3H]ERGO after oral administration was higher in octn1(-/-) mice than in wildtype mice, despite the lower absorption in octn1(-/-) mice. This was probably because of efficient hepatic uptake of [3H]ERGO, as revealed by integration plot analysis; the uptake clearance was close to the hepatic plasma flow rate. The uptake of [ 3H]ERGO by isolated hepatocytes was minimal, whereas [ 3H]ERGO uptake was observed in isolated nonparenchymal cells. This finding is consistent with immunostaining of OCTN1 in liver sinusoids. Thus, our results indicate that OCTN1 is functionally expressed in nonparenchymal liver cells.

Original languageEnglish
Pages (from-to)1665-1672
Number of pages8
JournalDrug Metabolism and Disposition
Volume38
Issue number10
DOIs
Publication statusPublished - 2010 Oct 1

Fingerprint

Carnitine
Small Intestine
Cations
Liver
Oral Administration
Ergothioneine
Gene Knockout Techniques
Tetraethylammonium
Intestinal Absorption
Verapamil
Knockout Mice
Hepatocytes
Kidney
Genes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver. / Sugiura, Tomoko; Kato, Sayaka; Shimizu, Takuya; Wakayama, Tomohiko; Nakamichi, Noritaka; Kubo, Yoshiyuki; Iwata, Daisuke; Suzuki, Kazuhiro; Soga, Tomoyoshi; Asano, Masahide; Iseki, Shoichi; Tamai, Ikumi; Tsuji, Akira; Kato, Yukio.

In: Drug Metabolism and Disposition, Vol. 38, No. 10, 01.10.2010, p. 1665-1672.

Research output: Contribution to journalArticle

Sugiura, T, Kato, S, Shimizu, T, Wakayama, T, Nakamichi, N, Kubo, Y, Iwata, D, Suzuki, K, Soga, T, Asano, M, Iseki, S, Tamai, I, Tsuji, A & Kato, Y 2010, 'Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver', Drug Metabolism and Disposition, vol. 38, no. 10, pp. 1665-1672. https://doi.org/10.1124/dmd.110.032763
Sugiura, Tomoko ; Kato, Sayaka ; Shimizu, Takuya ; Wakayama, Tomohiko ; Nakamichi, Noritaka ; Kubo, Yoshiyuki ; Iwata, Daisuke ; Suzuki, Kazuhiro ; Soga, Tomoyoshi ; Asano, Masahide ; Iseki, Shoichi ; Tamai, Ikumi ; Tsuji, Akira ; Kato, Yukio. / Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver. In: Drug Metabolism and Disposition. 2010 ; Vol. 38, No. 10. pp. 1665-1672.
@article{2bc39fede05f45a684bda0f701d68cbc,
title = "Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver",
abstract = "Carnitine/organic cation transporter (OCTN1/SLC22A4) accepts various therapeutic agents as substrates in vitro and is expressed ubiquitously, although its function in most organs has not yet been examined. The purpose of the present study was to evaluate functional expression of OCTN1 in small intestine and liver, using octn1 gene knockout [octn1(-/-)] mice. After oral administration of [3H]ergothioneine ([3H]ERGO), a typical substrate of OCTN1, the amount of [3H]ERGO remaining in the small intestinal lumen was much higher in octn1(-/-) mice than in wild-type mice. In addition, uptake of [3H]ERGO by human embryonic kidney 293 cells heterologously expressing OCTN1 gene product and uptake of [3H]ERGO at the apical surface of intestinal everted sacs from wild-type mice were inhibited by OCTN1 substrates, tetraethylammonium and verapamil. Immunohistochemical analysis revealed that OCTN1 is localized on the apical surface of small intestine in mice and humans. These results suggest that OCTN1 is responsible for small intestinal absorption of [3H]ERGO. However, the plasma concentration of [3H]ERGO after oral administration was higher in octn1(-/-) mice than in wildtype mice, despite the lower absorption in octn1(-/-) mice. This was probably because of efficient hepatic uptake of [3H]ERGO, as revealed by integration plot analysis; the uptake clearance was close to the hepatic plasma flow rate. The uptake of [ 3H]ERGO by isolated hepatocytes was minimal, whereas [ 3H]ERGO uptake was observed in isolated nonparenchymal cells. This finding is consistent with immunostaining of OCTN1 in liver sinusoids. Thus, our results indicate that OCTN1 is functionally expressed in nonparenchymal liver cells.",
author = "Tomoko Sugiura and Sayaka Kato and Takuya Shimizu and Tomohiko Wakayama and Noritaka Nakamichi and Yoshiyuki Kubo and Daisuke Iwata and Kazuhiro Suzuki and Tomoyoshi Soga and Masahide Asano and Shoichi Iseki and Ikumi Tamai and Akira Tsuji and Yukio Kato",
year = "2010",
month = "10",
day = "1",
doi = "10.1124/dmd.110.032763",
language = "English",
volume = "38",
pages = "1665--1672",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "10",

}

TY - JOUR

T1 - Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver

AU - Sugiura, Tomoko

AU - Kato, Sayaka

AU - Shimizu, Takuya

AU - Wakayama, Tomohiko

AU - Nakamichi, Noritaka

AU - Kubo, Yoshiyuki

AU - Iwata, Daisuke

AU - Suzuki, Kazuhiro

AU - Soga, Tomoyoshi

AU - Asano, Masahide

AU - Iseki, Shoichi

AU - Tamai, Ikumi

AU - Tsuji, Akira

AU - Kato, Yukio

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Carnitine/organic cation transporter (OCTN1/SLC22A4) accepts various therapeutic agents as substrates in vitro and is expressed ubiquitously, although its function in most organs has not yet been examined. The purpose of the present study was to evaluate functional expression of OCTN1 in small intestine and liver, using octn1 gene knockout [octn1(-/-)] mice. After oral administration of [3H]ergothioneine ([3H]ERGO), a typical substrate of OCTN1, the amount of [3H]ERGO remaining in the small intestinal lumen was much higher in octn1(-/-) mice than in wild-type mice. In addition, uptake of [3H]ERGO by human embryonic kidney 293 cells heterologously expressing OCTN1 gene product and uptake of [3H]ERGO at the apical surface of intestinal everted sacs from wild-type mice were inhibited by OCTN1 substrates, tetraethylammonium and verapamil. Immunohistochemical analysis revealed that OCTN1 is localized on the apical surface of small intestine in mice and humans. These results suggest that OCTN1 is responsible for small intestinal absorption of [3H]ERGO. However, the plasma concentration of [3H]ERGO after oral administration was higher in octn1(-/-) mice than in wildtype mice, despite the lower absorption in octn1(-/-) mice. This was probably because of efficient hepatic uptake of [3H]ERGO, as revealed by integration plot analysis; the uptake clearance was close to the hepatic plasma flow rate. The uptake of [ 3H]ERGO by isolated hepatocytes was minimal, whereas [ 3H]ERGO uptake was observed in isolated nonparenchymal cells. This finding is consistent with immunostaining of OCTN1 in liver sinusoids. Thus, our results indicate that OCTN1 is functionally expressed in nonparenchymal liver cells.

AB - Carnitine/organic cation transporter (OCTN1/SLC22A4) accepts various therapeutic agents as substrates in vitro and is expressed ubiquitously, although its function in most organs has not yet been examined. The purpose of the present study was to evaluate functional expression of OCTN1 in small intestine and liver, using octn1 gene knockout [octn1(-/-)] mice. After oral administration of [3H]ergothioneine ([3H]ERGO), a typical substrate of OCTN1, the amount of [3H]ERGO remaining in the small intestinal lumen was much higher in octn1(-/-) mice than in wild-type mice. In addition, uptake of [3H]ERGO by human embryonic kidney 293 cells heterologously expressing OCTN1 gene product and uptake of [3H]ERGO at the apical surface of intestinal everted sacs from wild-type mice were inhibited by OCTN1 substrates, tetraethylammonium and verapamil. Immunohistochemical analysis revealed that OCTN1 is localized on the apical surface of small intestine in mice and humans. These results suggest that OCTN1 is responsible for small intestinal absorption of [3H]ERGO. However, the plasma concentration of [3H]ERGO after oral administration was higher in octn1(-/-) mice than in wildtype mice, despite the lower absorption in octn1(-/-) mice. This was probably because of efficient hepatic uptake of [3H]ERGO, as revealed by integration plot analysis; the uptake clearance was close to the hepatic plasma flow rate. The uptake of [ 3H]ERGO by isolated hepatocytes was minimal, whereas [ 3H]ERGO uptake was observed in isolated nonparenchymal cells. This finding is consistent with immunostaining of OCTN1 in liver sinusoids. Thus, our results indicate that OCTN1 is functionally expressed in nonparenchymal liver cells.

UR - http://www.scopus.com/inward/record.url?scp=77957126905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957126905&partnerID=8YFLogxK

U2 - 10.1124/dmd.110.032763

DO - 10.1124/dmd.110.032763

M3 - Article

VL - 38

SP - 1665

EP - 1672

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 10

ER -